Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Surface Self-Assembly, Film Morphology, and Charge Transport Properties of Semiconducting Triazoloarenes.

Wisman DL, Kim S, Morris TW, Choi J, Tempas CD, Trainor CQ, Lee D, Tait SL.

Langmuir. 2019 May 14;35(19):6304-6311. doi: 10.1021/acs.langmuir.9b00512. Epub 2019 May 1.

PMID:
30977664
2.

Multi-electron Reduction Capacity and Multiple Binding Pockets in Metal-Organic Redox Assembly at Surfaces.

Morris TW, Huerfano IJ, Wang M, Wisman DL, Cabelof AC, Din NU, Tempas CD, Le D, Polezhaev AV, Rahman TS, Caulton KG, Tait SL.

Chemistry. 2019 Apr 11;25(21):5565-5573. doi: 10.1002/chem.201900002. Epub 2019 Mar 18.

PMID:
30746807
3.

Redox-active ligand controlled selectivity of vanadium oxidation on Au(100).

Tempas CD, Morris TW, Wisman DL, Le D, Din NU, Williams CG, Wang M, Polezhaev AV, Rahman TS, Caulton KG, Tait SL.

Chem Sci. 2018 Jan 4;9(6):1674-1685. doi: 10.1039/c7sc04752e. eCollection 2018 Feb 14.

4.

Impact of Surgical Specialty on Outcomes Following Carotid Endarterectomy.

Lieber BA, Henry JK, Agarwal N, Day JD, Morris TW 3rd, Stephens ML, Abla AA.

Neurosurgery. 2017 Feb 1;80(2):217-225. doi: 10.1093/neuros/nyw027.

PMID:
28175918
5.

Giant Recurrent Supratentorial Neurenteric Cyst As a Cause of Medically Refractory Epilepsy.

Morris TWI, Dowdy JT, Gokden M, Serletis D.

J Ark Med Soc. 2016 Dec;113(6):140-141.

PMID:
30047676
6.

Acanthamoeba encystment: multifactorial effects of buffers, biocides, and demulcents present in contact lens care solutions.

Kovacs CJ, Lynch SC, Rah MJ, Millard KA, Morris TW.

Clin Ophthalmol. 2015 Oct 13;9:1905-13. doi: 10.2147/OPTH.S88199. eCollection 2015.

7.

Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.

Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW.

JAMA Ophthalmol. 2015 Dec;133(12):1445-54. doi: 10.1001/jamaophthalmol.2015.3888.

PMID:
26502312
8.

Surveillance of the Activity of Aminoglycosides and Fluoroquinolones Against Ophthalmic Pathogens from Europe in 2010-2011.

Sanfilippo CM, Morrissey I, Janes R, Morris TW.

Curr Eye Res. 2016 May;41(5):581-9. doi: 10.3109/02713683.2015.1045084. Epub 2015 Jul 22.

PMID:
26200173
9.

Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.

Garg P, Mathur U, Sony P, Tandon R, Morris TW, Comstock TL.

Asia Pac J Ophthalmol (Phila). 2015 May-Jun;4(3):140-5. doi: 10.1097/APO.0000000000000055.

PMID:
26065499
10.

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.

Bucci FA Jr, Evans RE, Amico LM, Morris TW, Fluet AT, Sanfilippo CM, DeCory HH, Comstock TL.

Clin Ophthalmol. 2015 May 13;9:843-52. doi: 10.2147/OPTH.S83162. eCollection 2015.

11.

Unencapsulated Streptococcus pneumoniae from conjunctivitis encode variant traits and belong to a distinct phylogenetic cluster.

Valentino MD, McGuire AM, Rosch JW, Bispo PJ, Burnham C, Sanfilippo CM, Carter RA, Zegans ME, Beall B, Earl AM, Tuomanen EI, Morris TW, Haas W, Gilmore MS.

Nat Commun. 2014 Nov 12;5:5411. doi: 10.1038/ncomms6411.

12.

The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.

Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C.

Drugs R D. 2013 Dec;13(4):243-52. doi: 10.1007/s40268-013-0029-1.

13.

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones.

Haas W, Sanfilippo CM, Hesje CK, Morris TW.

Clin Ophthalmol. 2013;7:821-30. doi: 10.2147/OPTH.S44085. Epub 2013 May 3.

14.

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.

Silverstein BE, Morris TW, Gearinger LS, Decory HH, Comstock TL.

Clin Ophthalmol. 2012;6:1987-96. doi: 10.2147/OPTH.S35715. Epub 2012 Nov 30.

15.

Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.

Haas W, Gearinger LS, Hesje CK, Sanfilippo CM, Morris TW.

Adv Ther. 2012 May;29(5):442-55. doi: 10.1007/s12325-012-0023-y. Epub 2012 May 25.

PMID:
22644963
16.

Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.

DeLeon J, Silverstein BE, Allaire C, Gearinger LS, Bateman KM, Morris TW, Comstock TL.

Clin Drug Investig. 2012 May 1;32(5):303-17. doi: 10.2165/11632470-000000000-00000.

PMID:
22420526
17.

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.

Haas W, Gearinger LS, Usner DW, Decory HH, Morris TW.

Clin Ophthalmol. 2011;5:1369-79. doi: 10.2147/OPTH.S23519. Epub 2011 Sep 21.

18.

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.

Morris TW, Gearinger LS, Usner DW, Paterno MR, Decory HH, Comstock TL, Haas W.

Clin Ophthalmol. 2011;5:1359-67. doi: 10.2147/OPTH.S23518. Epub 2011 Sep 21.

19.
20.

High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis.

Haas W, Hesje CK, Sanfilippo CM, Morris TW.

Curr Eye Res. 2011 Dec;36(12):1078-85. doi: 10.3109/02713683.2011.624670. Epub 2011 Oct 11.

PMID:
21988450
21.

Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study.

Haas W, Pillar CM, Torres M, Morris TW, Sahm DF.

Am J Ophthalmol. 2011 Oct;152(4):567-574.e3. doi: 10.1016/j.ajo.2011.03.010. Epub 2011 Jun 8.

PMID:
21652021
22.

Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroquinolone besifloxacin.

Shinabarger DL, Zurenko GE, Hesje CK, Sanfilippo CM, Morris TW, Haas W.

J Chemother. 2011 Apr;23(2):80-6.

PMID:
21571623
23.
24.

In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.

Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW.

J Antimicrob Chemother. 2011 Apr;66(4):840-4. doi: 10.1093/jac/dkq531. Epub 2011 Jan 27.

PMID:
21393192
25.

Relevance of aqueous humor concentrations of fluoroquinolones.

Scassellati Sforzolini B, Sheets JW Jr, Morris TW.

J Cataract Refract Surg. 2011 Jan;37(1):217-8. doi: 10.1016/j.jcrs.2010.10.033. No abstract available.

PMID:
21183123
26.

Molecular epidemiology of methicillin-resistant and methicillin-susceptible Staphylococcus aureus isolated from the eye.

Hesje CK, Sanfilippo CM, Haas W, Morris TW.

Curr Eye Res. 2011 Feb;36(2):94-102. doi: 10.3109/02713683.2010.534229. Epub 2010 Dec 15.

27.

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis.

Comstock TL, Karpecki PM, Morris TW, Zhang JZ.

Clin Ophthalmol. 2010 Apr 26;4:215-25.

28.

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW.

J Antimicrob Chemother. 2010 Jul;65(7):1441-7. doi: 10.1093/jac/dkq127. Epub 2010 Apr 30.

29.

Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.

McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL, Usner DW.

Ophthalmology. 2009 Sep;116(9):1615-1623.e1. doi: 10.1016/j.ophtha.2009.05.014. Epub 2009 Jul 29.

PMID:
19643483
30.

Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.

Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW.

Antimicrob Agents Chemother. 2009 Aug;53(8):3552-60. doi: 10.1128/AAC.00418-09. Epub 2009 Jun 8.

31.

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.

Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL.

Curr Med Res Opin. 2009 May;25(5):1159-69. doi: 10.1185/03007990902837919 .

PMID:
19323612
32.

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.

Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS.

Antimicrob Agents Chemother. 2008 Jul;52(7):2313-23. doi: 10.1128/AAC.01649-07. Epub 2008 Apr 28.

33.

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.

Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS.

Antimicrob Agents Chemother. 2008 Jul;52(7):2324-34. doi: 10.1128/AAC.01651-07. Epub 2008 Apr 28.

34.

Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins.

Kim IH, Combrink KD, Ma Z, Chapo K, Yan D, Renick P, Morris TW, Pulse M, Simecka JW, Ding CZ.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1181-4. Epub 2006 Dec 12.

PMID:
17189695
35.

Development of a quantitative structure-activity relationship model for inhibition of gram-positive bacterial cell growth by biarylamides.

Stanton DT, Madhav PJ, Wilson LJ, Morris TW, Hershberger PM, Parker CN.

J Chem Inf Comput Sci. 2004 Jan-Feb;44(1):221-9.

PMID:
14741031
36.

Unique biological properties and molecular mechanism of 5,6-bridged quinolones.

Macinga DR, Renick PJ, Makin KM, Ellis DH, Kreiner AA, Li M, Rupnik KJ, Kincaid EM, Wallace CD, Ledoussal B, Morris TW.

Antimicrob Agents Chemother. 2003 Aug;47(8):2526-37.

37.

Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations.

Roychoudhury S, Twinem TL, Makin KM, Nienaber MA, Li C, Morris TW, Ledoussal B, Catrenich CE.

Antimicrob Agents Chemother. 2001 Dec;45(12):3422-6.

38.

The identification and characterization of hydrazinyl urea-based antibacterial agents through combinatorial chemistry.

Wilson LJ, Morris TW, Wu Q, Renick PJ, Parker CN, Davis MC, McKeever HD, Hershberger PM, Switzer AG, Shrum G, Sunder S, Jones DR, Soper SS, Dobson RL, Burt T, Morand KL, Stella M.

Bioorg Med Chem Lett. 2001 May 7;11(9):1149-52.

PMID:
11354364
39.

Effect of angiotensin converting enzyme inhibition on the Doppler waveform in dogs with renal artery stenosis.

Gottlieb RH, Zusman E, Hartley DF, Rubens DJ, Voci SL, Robinette W, Melendez L, Morris TW, Ojha S, Chengazi V, Erturk E, Messing EM.

J Ultrasound Med. 1999 Jul;18(7):481-7.

PMID:
10400051
40.

Application of nearest-neighbor and cluster analyses in pharmaceutical lead discovery.

Stanton DT, Morris TW, Roychoudhury S, Parker CN.

J Chem Inf Comput Sci. 1999 Jan-Feb;39(1):21-7.

PMID:
9987851
42.

Osmolality of contrast media affects opacification during renal arteriography.

Morris TW, Ning R, Hartley DF, Owusu K.

Acad Radiol. 1996 Aug;3 Suppl 2:S251-3. No abstract available.

PMID:
8796574
43.

Luminal diameter and vasa vasorum response to stent dilation in the rabbit aorta.

Sahler LG, Morris TW, Owusu KN, Gutierrez OH.

Acad Radiol. 1996 Jul;3(7):545-9.

PMID:
8796715
44.

Measurement of low mtK0s production from 14.6A GeV/c Si beams on a Pb target.

Ahmad S, Bonner BE, Buchanan JA, Chan CS, Chiou CN, Clement JM, Eiseman SE, Efstathiadis E, Etkin A, Foley KJ, Hackenburg RW, Hallman TJ, Kramer MA, Lindenbaum SJ, Longacre RS, Love WA, Madansky L, Morris TW, Mutchler GS, Platner ED, Saulys AC, Zhao K, Zhu Y.

Phys Rev C Nucl Phys. 1995 Nov;52(5):R2289-R2292. No abstract available.

PMID:
9970820
45.

Purification and properties of the lipoate protein ligase of Escherichia coli.

Green DE, Morris TW, Green J, Cronan JE Jr, Guest JR.

Biochem J. 1995 Aug 1;309 ( Pt 3):853-62.

46.
47.
49.

Angiography of the temporomandibular joint. Description of an experimental technique with initial results.

Takagi R, Shimoda T, Westesson PL, Takahashi A, Morris TW, Sano T, Moses JJ.

Oral Surg Oral Med Oral Pathol. 1994 Oct;78(4):539-43.

PMID:
7800385
50.

Supplemental Content

Loading ...
Support Center